The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Abstract
CONTEXT: Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. OBJECTIVES: Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components. DESIGN AND SETTING: This was a 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study with ongoing 78-wk site- and patient-blinded extension period at 40 sites in five countries. PATIENTS: Included were 182 patients with T2DM (mean values: women 63.3 and men 58.6 yr of age; hemoglobin A1c 7.17%, body mass index 31.9 kg/m2, and body weight 91.5 kg) inadequately controlled on metformin. INTERVENTION: Dapagliflozin 10 mg/d or placebo was added to open-label metformin for 24 wk. MAIN OUTCOME MEASURES: Primary endpoint was total body weight (TBW) change from baseline at wk 24. Key secondary endpoints were waist circumference and dual-energy x-ray absorptiometry total-body fat mass (FM) changes from baseline at wk 24, and patient proportion achieving body weight reduction of at least 5% at wk 24. In a subset of patients, magnetic resonance assessment of visceral adipose tissue (VAT) and sc adipose tissue (SAT) volume and hepatic lipid content were also evaluated. RESULTS: At wk 24, placebo-corrected changes with dapagliflozin were as follows: TBW, -2.08 kg [95% confidence interval (CI)=-2.84 to -1.31; P<0.0001]; waist circumference, -1.52 cm (95% CI=-2.74 to -0.31; P=0.0143); FM, -1.48 kg (95% CI=-2.22 to -0.74; P=0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI=15.5 to 36.7; P<0.0001); VAT, -258.4 cm3 (95% CI=-448.1 to -68.6; nominal P=0.0084); SAT, -184.9 cm3 (95% CI=-359.7 to -10.1; nominal P=0.0385). In the dapagliflozin vs. placebo groups, respectively, serious adverse events were reported in 6.6 vs. 1.1%; events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%; and lower urinary tract infections in 6.6 vs. 2.2%. CONCLUSIONS: Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Grundy, S. M. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.151092 · Cited by 1,616
de Koning, L., Merchant, A. T., Pogue, J., & Anand, S. S. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm026 · Cited by 1,073
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 725
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627
Is Glycemic Control Improving in U.S. Adults?
Hoerger, T. J., Segel, J. E., Gregg, E. W., & SAADDINE, J. B. (2007) · Diabetes Care · doi:10.2337/dc07-1572 · Cited by 477
Bays, H. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.038 · Cited by 431
Strojek, K., Yoon, K., Hrubá, V., Elze, M., Langkilde, A. M., & Parikh, S. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 410
Self-citationWilding, J. P. H., Norwood, P. C., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc09-0517 · Cited by 365
Self-citationJendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Clinical Applications of Body Composition Measurements Using DXA
Albanese, C. V., Dießel, E., & Genant, H. K. (2003) · Journal of Clinical Densitometry · doi:10.1385/jcd:6:2:75 · Cited by 276
Glucose transport by human renal Na + / d -glucose cotransporters SGLT1 and SGLT2
Hummel, C. S., Lü, C., Loo, D. D. F., Hirayama, B. A., Voss, A. A., & Wright, E. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00388.2010 · Cited by 273
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Nair, S., & Wilding, J. P. H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0473 · Cited by 264
Self-citationNorris, S. L., Zhang, X., Avenell, A., Gregg, E., Bowman, B., Serdula, M., Brown, T. J., Schmid, C. H., & Lau, J. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.024 · Cited by 253
Evaluation of risk factors for development of complications in Type II diabetes in Europe
Liebl, A., Mata, M., & Eschwége, E. (2002) · Diabetologia · doi:10.1007/s00125-002-0863-0 · Cited by 250
Harris, S. B., Ékoé, J.-M., Zdanowicz, Y., & Webster-Bogaert, S. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.024 · Cited by 237
How strong is the association between abdominal obesity and the incidence of type 2 diabetes?
Freemantle, N., Holmes, J., Hockey, A., & Kumar, S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01805.x · Cited by 236
Harder, H., Nielsen, L., Thi, T. D. T., & Astrup, A. V. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1915 · Cited by 230
Effect of Rosiglitazone on Insulin Sensitivity and Body Composition in Type 2 Diabetic Patients
Carey, D., Cowin, G., Galloway, G. J., Jones, N. P., Richards, J. C., Biswas, N., & Doddrell, D. M. (2002) · Obesity Research · doi:10.1038/oby.2002.137 · Cited by 210
Improving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates
Zhang, M., Tsiatis, A. A., & Davidian, M. (2008) · Biometrics · doi:10.1111/j.1541-0420.2007.00976.x · Cited by 208
Body composition assessment by dual-energy X-ray absorptiometry (DXA)
Andréoli, A., Scalzo, G., Masala, S. A., Tarantino, U., & Guglielmi, G. (2009) · La radiologia medica · doi:10.1007/s11547-009-0369-7 · Cited by 202
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial
Smith, S. R., de Jonge, L., Volaufova, J., Li, Y., Xie, H., & Bray, G. A. (2005) · Metabolism · doi:10.1016/j.metabol.2004.07.008 · Cited by 176
Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
Hermansen, K., & Mortensen, L. S. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00005 · Cited by 173
Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161
Basu, A., Jensen, M. D., McCann, F., Mukhopadhyay, D., Joyner, M. J., & Rizza, R. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-2004 · Cited by 144
Kasichayanula, S., Liu, X., Shyu, W. C., Zhang, W., Pfister, M., Griffen, S. C., Li, T., LaCreta, F. P., & Boulton, D. W. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01314.x · Cited by 93
Guisasola, F. Á., Mavros, P., Nocea, G., Alemao, E., Alexander, C. M., & Yin, D. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00881.x · Cited by 92
Glucagon-like peptide-1 analogues for type 2 diabetes
Wilding, J. P. H., & Hardy, K. J. (2011) · BMJ · doi:10.1136/bmj.d410 · Cited by 23
Self-citationGallwitz, B., Haupt, A., Kraus, P., Peters, N., Petto, H., Dotta, F., Petto, H., Poll, L. W., Rose, L., & Schernthaner, G.-H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01309.x · Cited by 9
Kullberg, J., Ortiz‐Nieto, F., & Johansson, L. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00979.x · Cited by 4
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Tang, 2003, The financing burden of treatment of diabetes-II and its symptom in urban China., Chin Health Econ, 12, 21
Cited by
Sorted by citations
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Metadata
- Authors
- Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S.
- Affiliations
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Aintree University Hospital (GB)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Corresponding author
- Bolinder, Jan
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-03-01
- Volume
- 97
- Issue
- 3
- Pages
- 1020-1031
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2167245776
- Cited by
- 867
- References
- 36
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 51 · 2023: 76 · 2022: 76 · 2021: 70 · 2020: 85 · 2019: 54 · 2018: 53 · 2017: 72 · 2016: 62 · 2015: 53 · 2014: 79 · 2013: 42 · 2012: 17
- FWCI
- 48.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, weight loss, body composition, fat mass, visceral adipose tissue, subcutaneous adipose tissue, hepatic fat content, metformin, inadequate glycemic control, waist circumference, fluid balance, urinary glucose excretion, glycemic control
- MeSH terms
- Adipose Tissue, Adult, Aged, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucosides, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Body Mass Index, Treatment Outcome, Body Fat Distribution, Sodium-Glucose Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
